Skip to main content
. 2021 Dec 10;15:4939–4959. doi: 10.2147/DDDT.S337925

Table 3.

Prodrug of Bisphosphonate for Tumor Treatment

Prodrug Structure Efficacy
12b80 compound82 graphic file with name DDDT_A_337925_O_ILF0009.jpg High affinity of bone support, specific release of doxorubicin, low cytotoxicity and cell uptake of prodrugs.
Bisphosphora–midate prodrug83 graphic file with name DDDT_A_337925_O_ILF0010.jpg Significantly enhanced anti-cancer activity
Tetrakis-pivaloyloxy–methyl 2-(thiazole-2-ylamino) ethylidene-1, 1- bisphosphonate (7)84 graphic file with name DDDT_A_337925_O_ILF0011.jpg Improve the effectiveness of related cancer immunotherapy
Prodrug micelles (alendronic acid - nanoparticle)85 graphic file with name DDDT_A_337925_O_ILF0012.jpg Reduce systemic toxicity, improve therapeutic effect
Doxorubicin bisphosphonate prodrug86 graphic file with name DDDT_A_337925_O_ILF0013.jpg Good stability and high affinity
2-(thiazole-2-ylamino) ethylidene-1, 1-bisphosphonate87 graphic file with name DDDT_A_337925_O_ILF0014.jpg Directly act on tumor growth, expand cytotoxic Vg2Vd2T cells in vitro, and enhance tumor control
Fluorine—containing zoledronate prodrug88 graphic file with name DDDT_A_337925_O_ILF0015.jpg Sensitize tumor cells for killing, expand Vγ2Vδ2 T cells for adoptive cell therapy